Trade

Strides Pharma Science share price

Balanced risk
  • 43%Low risk
  • 43%Moderate risk
  • 43%Balanced risk
  • 43%High risk
  • 43%Extreme risk
  • ₹855.20(3.62%)
    January 22, 2026 14:12:07 PM IST
    • NSE
    • BSE
  • Vol : 285.91 K (NSE + BSE)
    Last 20 day avg : 325.49 K

Strides Pharma Science is trading 3.62% upper at Rs 855.20 as compared to its last closing price. Strides Pharma Science has been trading in the price range of 866.00 & 837.50. Strides Pharma Science has given -8.39% in this year & -10.97% in the last 5 days. Strides Pharma Science has TTM P/E ratio 19.03 as compared to the sector P/E of 22.50.There are 1 analysts who have initiated coverage on Strides Pharma Science. There are 0.00 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0.00 analysts have given the stock a sell rating.The company posted a net profit of 127.53 Crores in its last quarter.Listed peers of Strides Pharma Science include Divi's Laboratories (1.12%), Cipla (0.14%), Torrent Pharmaceuticals (0.79%).The Mutual Fund holding in Strides Pharma Science was at 8.59% in 31 Dec 2025. The MF holding has increased from the last quarter. The FII holding in Strides Pharma Science was at 29.52% in 31 Dec 2025. The FII holding has increased from the last quarter.

  • Overview
  • Financials
  • Forecast
  • Technical Analysis
  • Peers
  • Shareholding
  • About the company
  • FAQ

Overview

  • 1 D
  • 5 D
  • 1 M
  • 3 M
  • 6 M
  • 1 Y
  • 5 Y
  • MAX
Explore on
Loading...
Key Metrics

Updated on Jan 22, 2026, 08:45 AM UTC

  • Beta
    Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
    0.80
    Low volatility
  • Debt To Equity
    The debt-to-equity ratio, indicating a company's financial leverage.
    0.74
    Higher than industry
  • Dividend Yield
    Annual dividends as a percentage of the stock price.
    0.47
    Lower than industry
  • P/B
    The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
    3.10
    Lower than historical values
  • P/E
    Price-to-earnings ratio based on trailing 12-month earnings
    19.93
    Lower than historical values
  • PEG Ratio
    The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
    0.39
    Indicates undervaluation
Price range
Day Range
Lowest
837.50
Highest
866.00
52 week range
Lowest
530.70
Highest
1,024.90
Strides Pharma Science News
Strides Pharma Science Peers
Return Comparison
Peers Comparison
Names
Technical ratingPrice%ChangeMarket CapP/EP/BDividend YieldDebt to Equity
Divi's Laboratories
Bearish
6,070.301.121,61,099.0978.6111.520.460.01
Cipla
Bearish
1,371.500.141,10,785.9122.953.870.870.81
Torrent Pharmaceuticals
Bullish
4,013.950.791,36,791.1267.3217.10.8317.62
Sun Pharmaceutical Industries
Bearish
1,614.050.093,87,844.8036.245.770.920.50
Dr Reddy's Laboratories
Moderately Bearish
1,216.505.281,01,528.0418.633.140.632.34
Mutual Fund Ownership
View all
WhiteOak Capital Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 4.62
  • % of AUM 1.39
Quant Business Cycle Fund Regular Growth
NA
  • Amount Invested (Cr.) 17.44
  • % of AUM 1.31
JM Small Cap Fund Regular Growth
NA
  • Amount Invested (Cr.) 8.96
  • % of AUM 1.24
Quant Active Fund Growth
4/5
  • Amount Invested (Cr.) 115.34
  • % of AUM 1.16
ITI Pharma and Healthcare Fund Regular Growth
NA
  • Amount Invested (Cr.) 2.24
  • % of AUM 1.01
Strides Pharma Science Corporate Actions
View all
  • Board Meetings
  • AGM
  • Dividends
  • Bonus
  • Split
  • Rights
Meeting DatePurpose
2025-10-31Quarterly Results
2025-07-29Quarterly Results
2025-05-22Audited Results & Final Dividend
2025-01-30Quarterly Results
2024-10-24Quarterly Results
About the company Strides Pharma Science
  • IndustryBiotechnology & Drugs
  • ISININE939A01011
  • BSE Code532531
  • NSE CodeSTAR
Strides Pharma Science Limited is an India-based pharmaceutical company. The Company is focused on the development and manufacture of IP-led niche finished dosage formulations. The Company operates through two segments: Pharmaceutical and Bio-pharmaceutical. Its geographical segment includes Africa, Australia, Asia (excluding India), North America, Europe, India, and Others. The Company manufactures a range of niche and pharmaceutical products, including a range of dosage forms such as liquids, creams and ointments, soft gels, sachets, tablets, and modified release dosage formats. It has eight manufacturing units located in India (Bengaluru-two sites, Puducherry, and Chennai), Singapore, Italy (Milan), the United States (Florida) and Kenya (Nairobi). It is also engaged in manufacturing soft gelatin capsules. It develops and manufactures drugs in the anti-retroviral, anti-malarial, anti-tuberculosis, hepatitis, and other infectious disease drug segments for its institutional business.
  • Management Info
  • Badree KomandurChief Executive Officer, Managing Director, Executive Director
  • Vikesh KumarGroup Chief Financial Officer and Chief Investor Relations Officer
  • Ramaraju PvsChief Operating Officer
  • Surabhi LoshaliGroup Chief Human Resources Officer
  • Manjula RamamurthyCompliance Officer, Company Secretary
  • Aditya KumarExecutive Director - Business Development
  • Umesh KaleChief of Quality Services
Strides Pharma Science Share Price FAQs

Strides Pharma Science is trading at 855.20 as on Thu Jan 22 2026 08:42:07. This is 3.62% upper as compared to its previous closing price of 825.35.

The market capitalization of Strides Pharma Science is 7874.97 Cr as on Thu Jan 22 2026 08:42:07.

The average broker rating on Strides Pharma Science is Buy. The breakup of analyst rating is given below -

  • 0.00 analysts have given a strong buy rating
  • 1 analysts have given a buy rating
  • 0.00 analysts have given a hold rating
  • 0.00 analysts have given a sell rating
  • 0.00 analysts have given a strong sell rating

The 52 wk high for Strides Pharma Science is 1024.90 whereas the 52 wk low is 530.70

Strides Pharma Science can be analyzed on the following key metrics -

  • TTM P/E: 19.03
  • Sector P/E: 22.50
  • Dividend Yield: 0.48%
  • D/E ratio: 0.67

Strides Pharma Science reported a net profit of 3593.46 Cr in 2025.

The Mutual Fund Shareholding was 8.59% at the end of 31 Dec 2025.

Quick Links
EQUITY QUICK LINKS
Strides Pharma Science QUICK LINKS
FROM MARKETS
RELATED LINKS
Quarterly Results
Business News/Market/Market Stats/  Strides Pharma Science share price
✕

Wait for it…

Log in to our website to save your bookmarks. It'll just take a moment.

✕

Wait for it…

Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.